Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cytokinetics Inc (CYTK) vs SPDR Gold Trust (GLD) Price & Performance

Cytokinetics IncTrade
SPDR Gold TrustTrade

Price performance (Past 24H)

Key statistics

Cytokinetics Inc vs SPDR Gold Trust — how do they compare? Cytokinetics Inc trades at $77.39 (market cap $10.78B), while SPDR Gold Trust trades at $405.04. The key difference: Cytokinetics Inc is trading nearer its 52-week high, SPDR Gold Trust nearer its low. Which is the better fit depends on your goals.

CYTKGLD
Market Cap
$10.78B
Sector
Technology
52-Week High
$87.26$495.90
52-Week Low
$34.31$305.27
Enterprise Value
$10.88B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cytokinetics Inc

Cytokinetics (CYTK) trades at $76.76, down 5.67% today, with a bearish technical signal and negative profitability metrics. Recent Q2 2026 earnings beat EPS estimates but missed on revenue, while the company's drug Myqorzo shows strong commercial uptake and regulatory approvals in the UK. Cash flow remains negative from operations, offset by financing activities.

The outlook is mixed: strong analyst buy ratings (97%) and a $111.14 price target suggest upside, but high cash burn, competitive pressures, and lack of profitability pose significant risks. Investment appeal hinges on successful drug commercialization and path to profitability.

SPDR Gold Trust

GLD trades at $398.47, up 2.26% in the past 24 hours, with a bullish technical signal driven by moving averages. The stock is near its pivot point of $399, with support at $397 and resistance at $400. Recent news highlights gold's rebound potential, citing central bank buying and softer Fed expectations as tailwinds. Financial ratios are unavailable, but the ETF's performance aligns with spot gold trends, which have gained momentum from geopolitical and macroeconomic factors.

The outlook for GLD is positive, with technical strength and supportive sentiment suggesting potential upside toward $402–$404 resistance. Risks include sensitivity to interest rate shifts and dollar strength, while analyst optimism centers on gold's safe-haven appeal. Investors should weigh ETF costs against physical gold alternatives, as momentum may hinge on sustained demand and economic data.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Cytokinetics Inc

Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.

Read more on CYTK

About SPDR Gold Trust

GLD is the largest physically backed gold ETF in the world. It offers investors a cost-efficient and secure way to track the price of gold bullion without the need for physical storage.

Read more on GLD